Appointments at Xoma and Watson Pharmaceuticals, plus a new role for Fred Hasaan – People on the move
Xoma has appointed James Neal as vice president (VP), business development. Neal has more than 25 years experience in the industry, most recently as acting CEO of Entelos where he inked deals with Eli Lilly and GlaxoSmithKline.
He also gained experience of collaborating with big pharma during his time at Iconix Biosciences and Incyte Genomics. Prior to this he worked at Monsanto.
Robert Stewart has been appointed as senior VP of global operations at Watson Pharmaceuticals. In this newly created position Stewart will oversee global manufacturing, supply chain, quality and technical operations of the business.
Stewart previously worked for eight years at Abbott Laboratories. Watson also changed Thomas Russillo’s job from executive VP and president of the generics division to executive VP, global generics.
William Callahan has been promoted to VP, operations at Depomed. Callahan joined Depomed in 2002, most recently working as senior director, operations, and over his 20 year career has also spent time at Avocet Medical, Cygnus Therapeutics and Applied Biosystems.
The European Generic Medicines Association (EGA) has elected Didier Barret as its president for a two-year term. Barret is president of Mylan Europe, Middle East and Africa.
Fred Hasaan has joined US private equity firm Warburg Pincus as senior advisor. Hasaan will use his industry experience, most recently as chairman and CEO of Schering-Plough, to advise the Warburg Pincus healthcare group.
Caleco Pharma has appointed Jim Metropoulos to its product development advisory board. Metropoulos has served as senior executive in the healthcare sector for 17 years, holding positions at Lowe McAdams Healthcare Worldwide and Sudler & Hennessey.
Mirna Therapeutics has appointed Paul Lammers as president and CEO. Before joining Mirna Lammers was president of Repros Therapeutics and has also worked at EMD Serono and Organon.
